Long term follow-up of patients with newly diagnosed glioblastoma treated by intraoperative photodynamic therapy: an update from the INDYGO trial (NCT03048240)
Journal of Neuro-Oncology · 2024-07 · 168 (3) · 495-505
DOI: 10.1007/s11060-024-04693-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 16.05.2024. Verfasst von Iulia Peciu-Florianu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Neurosurgery Department, CHU-Lille, F-59000, Lille, France. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Photochemotherapy, Aminolevulinic Acid. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Glioblastoma remains incurable despite optimal multimodal management. The interim analysis of open label, single arm INDYGO pilot trial showed actuarial 12-months progression-free survival (PFS) of 60% (median 17.1 months), actuarial 12-months overall survival (OS) of 80% (median 23.1 months). We report updated, exploratory analyses of OS, PFS, and health-related quality of life (HRQOL) for patients receiving intraoperative photodynamic therapy (PDT) with 5-aminolevulinic acid hydrochloride (5-ALA HCl).
Methods
Ten patients were included (May 2017 – April 2021) for standardized therapeutic approach including 5-ALA HCl fluorescence-guided surgery (FGS), followed by intraoperative PDT with a single 200 J/cm 2 dose of light. Postoperatively, patients received adjuvant therapy (Stupp protocol) then followed every 3 months (clinical and cerebral MRI) and until disease progression and/or death. Procedure safety and toxicity occurring during the first four weeks after PDT were assessed. Data concerning relapse, HRQOL and survival were prospectively collected and analyzed.
Results
At the cut-off date (i.e., November 1st 2023), median follow-up was 23 months (9,7–71,4). No unacceptable or unexpected toxicities and no treatment-related deaths occurred during the study. Kaplan–Meier estimated 23.4 months median OS, actuarial 12-month PFS rate 60%, actuarial 12-month, 24-month, and 5-year OS rates 80%, 50% and 40%, respectively. Four patients were still alive (1 patient free of recurrence).
Conclusion
At 5 years-follow-up, intraoperative PDT with surgical maximal excision as initial therapy and standard adjuvant treatment suggests an increase of time to recurrence and overall survival in a high proportion of patients. Quality of life was maintained without any severe side effects.
Trial registration
NCT number NCT03048240. EudraCT number: 2016–002706-39.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurosurgery Department, CHU-Lille, F-59000, Lille, France.
- Neuroradiology Department, CHU-Lille, F-59000, Lille, France.
- Neuro-Oncology Department, CHU-Lille, F-59000, Lille, France.
- Hemerion Therapeutics, Villeneuve D'Ascq, France.
- Neurosurgery Department, CHU-Lille, F-59000, Lille, France. nicolas.reyns@chru-lille.fr.
- U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, University of Lille, INSERM, CHU-Lille, F-59000, Lille, France. nicolas.reyns@chru-lille.fr.
Zitieren
APA
Peciu-Florianu, I., Vannod-Michel, Q., Vauleon, E., Bonneterre, M. E., & Reyns, N. (2024). Long term follow-up of patients with newly diagnosed glioblastoma treated by intraoperative photodynamic therapy: an update from the INDYGO trial (NCT03048240). Journal of Neuro-Oncology, 168(3), 495-505. https://doi.org/10.1007/s11060-024-04693-4
Vancouver
Peciu-Florianu I, Vannod-Michel Q, Vauleon E, Bonneterre ME, Reyns N. Long term follow-up of patients with newly diagnosed glioblastoma treated by intraoperative photodynamic therapy: an update from the INDYGO trial (NCT03048240). Journal of Neuro-Oncology. 2024;168(3):495-505. doi:10.1007/s11060-024-04693-4
BibTeX
@article{PeciuFlorianu2024,
author = {Peciu-Florianu, Iulia and Vannod-Michel, Quentin and Vauleon, Enora and Bonneterre, Marie-Edith and Reyns, Nicolas},
title = {Long term follow-up of patients with newly diagnosed glioblastoma treated by intraoperative photodynamic therapy: an update from the INDYGO trial (NCT03048240)},
journal = {Journal of Neuro-Oncology},
year = {2024},
volume = {168},
number = {3},
pages = {495--505},
doi = {10.1007/s11060-024-04693-4}
}
EUVIMED